RG6289
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RG6289, covering 2025-08-03 to 2025-08-03. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease [Phase 2, Phase 3]